Lisata Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Lisata Therapeutics has filed definitive additional materials related to its proxy statement with the SEC.
NASDAQ
Lisata Therapeutics is holding its 2025 Annual Meeting of Stockholders to vote on key proposals including the election of directors, an amendment to the Employee Stock Purchase Plan, and the ratification of auditors.
NASDAQ
Lisata Therapeutics has filed a definitive proxy statement with the SEC.
NASDAQ
Lisata Therapeutics is holding its 2024 Annual Meeting of Stockholders on June 27, 2024, to vote on director elections, equity incentive plan amendments, employee stock purchase plan amendments, auditor ratification, and executive compensation.